Ignite Creation Date:
2024-07-17 @ 11:51 AM
Last Modification Date:
2024-10-26 @ 3:34 PM
Study NCT ID:
NCT06499922
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-07-15
First Post:
2024-05-31
Brief Title:
Surgical Management of Low Grade Glioma
Sponsor:
Assiut University
Organization:
Assiut University
Study Overview
Official Title:
Recent Advances in Surgical Management of Low Grade Glioma
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To assess the morbidity and mortality in low grade glioma patients following surgical management
Detailed Description:
lower-grade gliomas histological diagnosis has had a long history each iteration of disease classification suffered from continued variability with detrimental consequences on prognostic precision and treatment decision making
In the WHO 2021 classification there are three primary categories of adult-type diffuse gliomas isocitrate dehydrogenase IDH-mutant 1p19q codeleted oligodendroglioma IDH-mutant non-codeleted astrocytoma and IDH-wildtype glioblastoma Diffuse low-grade glioma is classified as WHO grade 1 and 2 astrocytoma with IDH mutation or oligodendroglioma with IDH mutation and 1p19q codeletion
The presence of the IDH1 mutation has become a defining factor for adult diffuse low-grade glioma Roughly 70 of grade 2-3 gliomas harbor mutations in either IDH1 or its mitochondrial counterpart IDH2
Although lower-grade gliomas may present in various ways the most common manifestation is seizures and the development of seizures during the course of the disease may herald tumor progression Among grade II tumors the incidence of epilepsy is higher with IDH mutation Anaplastic gliomas are somewhat less likely to manifest with seizures 57 and are more likely than grade II gliomas to produce mental status vision and motor deficits
In the WHO 2021 classification there are three primary categories of adult-type diffuse gliomas isocitrate dehydrogenase IDH-mutant 1p19q codeleted oligodendroglioma IDH-mutant non-codeleted astrocytoma and IDH-wildtype glioblastoma Diffuse low-grade glioma is classified as WHO grade 1 and 2 astrocytoma with IDH mutation or oligodendroglioma with IDH mutation and 1p19q codeletion
The presence of the IDH1 mutation has become a defining factor for adult diffuse low-grade glioma Roughly 70 of grade 2-3 gliomas harbor mutations in either IDH1 or its mitochondrial counterpart IDH2
Although lower-grade gliomas may present in various ways the most common manifestation is seizures and the development of seizures during the course of the disease may herald tumor progression Among grade II tumors the incidence of epilepsy is higher with IDH mutation Anaplastic gliomas are somewhat less likely to manifest with seizures 57 and are more likely than grade II gliomas to produce mental status vision and motor deficits
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None